LABU stock forecast, quote, news & analysis

Key Takeaways

• LABU advanced roughly 25% over the trailing 30 days, rising from about $253.68 to $317.20, as a rally in small- and mid-cap biotech stocks was amplified by the fund's 3x daily leverage.
• Over the trailing quarter, the fund climbed approximately 77%, reflecting sustained momentum across the S&P Biotechnology Select Industry Index.
• LABU seeks 300% of the daily return of its underlying index, making it a high-volatility trading vehicle rather than a long-term buy-and-hold instrument.
• Nearly all of the fund's equity exposure sits in healthcare (about 100%), concentrated across equal-weighted small- and mid-cap biotech names.
• Recent performance has been driven by broad biotech leadership, clinical and regulatory catalysts, and a macro backdrop generally supportive of long-duration growth equities.

Direxion Daily S&P Biotech Bull 3X Shares (LABU) Overview and Portfolio Exposure

LABU is a leveraged exchange-traded fund (ETF) managed by Direxion that seeks daily investment results, before fees and expenses, equal to 300% of the performance of the S&P Biotechnology Select Industry Index. Launched in 2015, the fund holds roughly 157 to 173 positions and uses swap agreements, index securities, and ETFs that track the index to achieve its leveraged exposure, with a net expense ratio of about 0.96%. The fund held more than $570 million in assets under management (AUM) as of mid-2026.

Because the underlying index is equal-weighted and focused on smaller biotechnology companies, the fund's equity exposure is spread across numerous modest single-stock positions rather than a handful of mega-caps. Top underlying holdings have recently included Apellis Pharmaceuticals (APLS), Revolution Medicines (RVMD), Travere Therapeutics (TVTX), Arrowhead Pharmaceuticals (ARWR), Alkermes (ALKS), Madrigal Pharmaceuticals (MDGL), Moderna (MRNA), and Viking Therapeutics (VKTX). Healthcare accounts for nearly all of the fund's sector exposure.

This structure helps explain the fund's behavior: an equal-weighted basket of small- and mid-cap biotech names carries far higher beta and volatility than a diversified large-cap index, and the 3x daily multiplier compounds that volatility in both directions.

Direxion Daily S&P Biotech Bull 3X Shares (LABU) Price Performance: Last 30 Days vs. Quarter

Over the trailing 30 days, LABU advanced approximately 25%, rising from around $253.68 to $317.20. The move was not linear: the fund endured sharp intraday swings, including a pullback from early-July highs near $324 before resuming higher into mid-August. Over the trailing quarter, the gain was substantially larger at roughly 77%, climbing from about $179.63 to $317.20.

Both periods reflect a trend-driven but volatile advance typical of leveraged biotech products. Because the fund's 3x exposure resets daily, multi-week returns are not simply three times the index return; path dependence can materially alter cumulative results during choppy stretches.

What Drove LABU Price in the Last 30 Days

The recent surge primarily reflects strength in the underlying S&P Biotechnology Select Industry Index. Leadership among small- and mid-cap biotech companies—spanning clinical-stage drug developers and emerging commercial franchises—drove the advance, which the fund's leverage then amplified on a daily basis.

Several themes supported the biotech complex. A steady cadence of clinical trial data readouts, FDA regulatory decisions, and M&A (mergers and acquisitions) activity historically lift the equal-weighted index, and investor sentiment toward the sector improved accordingly. Expectations for a more accommodative interest-rate environment also tend to support long-duration, cash-intensive growth companies whose valuations are sensitive to discount rates. These sector-wide forces, rather than any single holding, accounted for most of the fund's move, given that individual index constituents each represent only a small fraction of assets.

What Drove LABU Performance Over the Last Quarter

The broader three-month trend reflects a more sustained rotation into biotech and innovation-oriented growth. Easing rate expectations, improving risk appetite for small-cap equities, and a favorable backdrop for drug-development economics supported the underlying index through the period. Institutional ETF flows into the healthcare and biotech complex reinforced the move, while clinical and regulatory milestones provided recurring catalysts.

Because LABU's returns are magnified relative to the index, the same drivers that lifted the equal-weighted biotech basket produced outsized fund performance over the quarter. The leveraged structure means that even moderate index gains translated into significantly larger fund-level returns, while episodic drawdowns were similarly amplified.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery platform that helps investors scan thousands of securities using technical indicators, fundamentals, volatility metrics, price patterns, industry filters, AI-generated signals, and performance characteristics. The tool is designed to streamline the research process, surfacing securities that match a user's chosen criteria far more efficiently than manual screening. For investors looking to monitor biotech leadership, sector momentum, or new breakout candidates across the market, the AI Screener offers a practical starting point for building a watchlist and refining an investment process.

LABU ETF Outlook: What Investors Should Watch Next

Going forward, investors should monitor the same forces that have driven recent performance. The FDA approval calendar and late-stage clinical trial readouts will remain key catalysts for the underlying index, alongside the pace of biotech M&A. Interest-rate expectations and inflation data will influence valuations for long-duration growth equities, while broader risk appetite and small-cap sentiment will shape sector leadership.

The fund's leveraged structure introduces additional considerations. Daily resets create volatility decay and path dependency, meaning returns over holding periods longer than a single day can diverge materially from three times the index's cumulative return, particularly in range-bound or choppy markets. These structural characteristics underscore that LABU is designed for short-term tactical use and active risk management rather than passive, long-term positioning.

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations